Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. Additionally, it offers meniscal repair system. It primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone44-20-7401-7646
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.90 billion
Profitability
Miscellaneous
Employees16,377
Next Earnings DateN/A
OptionableOptionable
Smith & Nephew (NYSE:SNN) Frequently Asked Questions
What is Smith & Nephew's stock symbol?
Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."
How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?
Smith & Nephew announced a semiannual dividend on Friday, February 15th. Stockholders of record on Friday, April 5th will be paid a dividend of $0.44 per share on Wednesday, May 8th. This represents a dividend yield of 2.31%. The ex-dividend date is Thursday, April 4th. This is a positive change from Smith & Nephew's previous semiannual dividend of $0.25. View Smith & Nephew's Dividend History.
How were Smith & Nephew's earnings last quarter?
Smith & Nephew plc (NYSE:SNN) issued its quarterly earnings data on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.39 by $0.59. View Smith & Nephew's Earnings History.
What guidance has Smith & Nephew issued on next quarter's earnings?
Smith & Nephew issued an update on its FY 2019 earnings guidance on Thursday, May, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.05112-5.07564 billion.
What price target have analysts set for SNN?
7 equities research analysts have issued 1 year price objectives for Smith & Nephew's stock. Their forecasts range from $6.00 to $6.00. On average, they expect Smith & Nephew's stock price to reach $6.00 in the next twelve months. This suggests that the stock has a possible downside of 85.8%. View Analyst Price Targets for Smith & Nephew.
What is the consensus analysts' recommendation for Smith & Nephew?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Smith & Nephew.
Has Smith & Nephew been receiving favorable news coverage?
News headlines about SNN stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Smith & Nephew earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Smith & Nephew's key competitors?
Some companies that are related to Smith & Nephew include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Align Technology (ALGN), Zimmer Biomet (ZBH), Steris (STE), DEMANT A S/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Wound Management Technologies (WNDM), Establishment Labs (ESTA), RTI Surgical (RTIX), ConforMIS (CFMS) and Invacare (IVC).
What other stocks do shareholders of Smith & Nephew own?
Who are Smith & Nephew's key executives?
Smith & Nephew's management team includes the folowing people:
- Mr. Namal Nawana, CEO & Exec. Director (Age 48)
- Mr. Graham Timothy Baker, CFO & Exec. Director (Age 51)
- Mr. Mark Gladwell, Pres of Global Operations (Age 44)
- Ms. Catheryn O'Rourke, Chief Legal & Compliance Officer (Age 46)
- Mr. Joe Metzger, Sr. VP of Marketing Services & Communications
Who are Smith & Nephew's major shareholders?
Smith & Nephew's stock is owned by a number of of institutional and retail investors. Top institutional investors include Cambiar Investors LLC (1.24%), Iridian Asset Management LLC CT (0.53%), FMR LLC (0.31%), Parametric Portfolio Associates LLC (0.17%), Northern Trust Corp (0.16%) and Goldman Sachs Group Inc. (0.10%).
Which institutional investors are selling Smith & Nephew stock?
SNN stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Boston Common Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., Cambiar Investors LLC, OLD Mission Capital LLC, Wells Fargo & Company MN, Jarislowsky Fraser Ltd and Envestnet Asset Management Inc..
Which institutional investors are buying Smith & Nephew stock?
SNN stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Renaissance Technologies LLC, Dalton Greiner Hartman Maher & Co., Dorsey Wright & Associates, Henry James International Management Inc., Goldman Sachs Group Inc. and Laurion Capital Management LP.
How do I buy shares of Smith & Nephew?
Shares of SNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Smith & Nephew's stock price today?
One share of SNN stock can currently be purchased for approximately $42.17.
How big of a company is Smith & Nephew?
Smith & Nephew has a market capitalization of $18.44 billion and generates $4.90 billion in revenue each year. The medical equipment provider earns $663 million in net income (profit) each year or $2.02 on an earnings per share basis. Smith & Nephew employs 16,377 workers across the globe.
What is Smith & Nephew's official website?
How can I contact Smith & Nephew?
Smith & Nephew's mailing address is 15 ADAM STREET, LONDON X0, WC2N 6LA. The medical equipment provider can be reached via phone at 44-20-7401-7646 or via email at [email protected]
MarketBeat Community Rating for Smith & Nephew (NYSE SNN)
MarketBeat's community ratings are surveys of what our community members think about Smith & Nephew and other stocks. Vote "Outperform" if you believe SNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNN will underperform the S&P 500 over the long term. You may vote once every thirty days.
